Kirr Marbach & Co. LLC IN Has $8.87 Million Holdings in Innospec Inc. (NASDAQ:IOSP)

Kirr Marbach & Co. LLC IN raised its position in shares of Innospec Inc. (NASDAQ:IOSPFree Report) by 0.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 78,443 shares of the specialty chemicals company’s stock after acquiring an additional 281 shares during the period. Innospec comprises about 2.0% of Kirr Marbach & Co. LLC IN’s investment portfolio, making the stock its 20th largest holding. Kirr Marbach & Co. LLC IN’s holdings in Innospec were worth $8,871,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. DekaBank Deutsche Girozentrale acquired a new stake in Innospec during the 1st quarter valued at $66,000. CWM LLC boosted its stake in Innospec by 239.6% in the second quarter. CWM LLC now owns 635 shares of the specialty chemicals company’s stock worth $78,000 after purchasing an additional 448 shares in the last quarter. nVerses Capital LLC grew its holdings in shares of Innospec by 200.0% during the third quarter. nVerses Capital LLC now owns 900 shares of the specialty chemicals company’s stock worth $102,000 after purchasing an additional 600 shares during the last quarter. Motco acquired a new stake in shares of Innospec in the first quarter valued at $132,000. Finally, EntryPoint Capital LLC bought a new position in shares of Innospec in the first quarter valued at about $147,000. Institutional investors own 96.64% of the company’s stock.

Innospec Price Performance

IOSP opened at $113.31 on Friday. The company’s 50 day simple moving average is $111.26 and its 200-day simple moving average is $119.99. Innospec Inc. has a one year low of $95.69 and a one year high of $133.71. The stock has a market capitalization of $2.83 billion, a P/E ratio of 18.98 and a beta of 1.07.

Innospec (NASDAQ:IOSPGet Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The specialty chemicals company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.02. The firm had revenue of $435.00 million for the quarter, compared to analyst estimates of $468.73 million. Innospec had a return on equity of 14.15% and a net margin of 7.90%. The business’s quarterly revenue was down 9.5% compared to the same quarter last year. During the same period last year, the company earned $1.28 EPS. As a group, analysts anticipate that Innospec Inc. will post 5.95 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Innospec from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 8th.

Read Our Latest Stock Analysis on IOSP

Insider Buying and Selling

In other Innospec news, CFO Ian Cleminson sold 3,398 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $114.74, for a total transaction of $389,886.52. Following the completion of the sale, the chief financial officer now directly owns 12,996 shares of the company’s stock, valued at approximately $1,491,161.04. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.35% of the company’s stock.

Innospec Company Profile

(Free Report)

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.

Further Reading

Want to see what other hedge funds are holding IOSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innospec Inc. (NASDAQ:IOSPFree Report).

Institutional Ownership by Quarter for Innospec (NASDAQ:IOSP)

Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.